Innovent Biologics Advances Efdamrofusp Alfa For Diabetic Macular Edema
Innovent Biologics Advances Efdamrofusp Alfa for Diabetic Macular Edema represents a significant advancement in the treatment of this debilitating eye condition. This innovative therapy offers a potential new approach to managing diabetic macular edema (DME), a leading cause of vision loss in individuals with diabetes. This discussion will explore the mechanism of action, clinical trial … Read more